ZINC000002107582
ZINC000002107582 is a UVRAG binder. ZINC000002107582 induces Apoptosis, increases intracellular ROS levels, arrests the cell cycle at the S phase, and elevates the proportion of cells in the Sub G0 phase. ZINC000002107582 exhibits anticancer activity against breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 859138-65-1
- Formule: C31H31NO6
- Masse moléculaire:513.58
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
ZINC000002107582 (0.195-50 μM; 24 h) potently inhibits MCF-7 cell viability with an IC50 of 5 μM, showing a concentration-dependent cytotoxic effect over 24 h[1].
ZINC000002107582 (5-10 μM; 24 h) induces dose-dependent apoptosis in MCF-7 cells, with 53.91% early apoptotic cells at IC50 (5 μM) and 80.67% total apoptotic cells at 2×IC50 (10 μM) after 24 h[1].
ZINC000002107582 (5-10 μM; 24 h) induces dose-dependent intracellular ROS accumulation in MCF-7 cells, with 71.51% ROS-positive cells at IC50 (5 μM) and 83.97% ROS-positive cells at 2×IC50 (10 μM) after 24 h[1].
ZINC000002107582 (5-10 μM; 24 h) induces S-phase cell cycle arrest and increases the Sub-G0 apoptotic population in MCF-7 cells, with more pronounced effects at 2×IC50 (10 μM) than at IC50 (5 μM) after 24 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human breast carcinoma MCF-7 cells
-
Concentration:0.195-50 μM
-
Incubation Time:24 h
-
Result:Caused a concentration-dependent reduction in cell viability.
Showed a slight reduction at 0.195-0.39 μM, a noticeable decrease at 0.781-3.125 μM, a pronounced reduction at 6.25-12.5 μM, and a significant decrease at 25-50 μM.
Reached a half-maximal inhibitory concentration (IC50) of 5 μM.
-
Cell Line:human breast carcinoma MCF-7 cells
-
Concentration:5 μM (IC50); 10 μM (2×IC50)
-
Incubation Time:24 h
-
Result:Resulted in 53.91% early apoptotic cells at IC50, while treatment at 2×IC50 resulted in 80.67% total apoptotic cells.
Showed a dose-dependent increase in apoptotic cell populations relative to untreated controls.
-
Cell Line:human breast carcinoma MCF-7 cells
-
Concentration:5 μM (IC50); 10 μM (2×IC50)
-
Incubation Time:24 h
-
Result:Reduced the G0/G1 population to 38.13%, increased the S-phase fraction to 25%, increased the Sub-G0 population to 6.82%, and decreased the G2/M phase to 25.69% at IC50.
Increased the S-phase fraction to 34%, increased the Sub-G0 population to 12.09%, decreased the G2/M phase to ~10%, and kept the G0/G1 fraction reduced relative to untreated controls at 2×IC50.
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- ROS/oxidative-stress fluorescent staining
- BrdU Incorporation Assay
- Apoptosis Solutions
- Protocol for Cell Cycle
- Breast Cancer Modeling
Chemical Information
-
CAS No. 859138-65-1
-
Masse moléculaire 513.58
-
Formule C31H31NO6
-
SMILES
O=C(C1(C2=CC=CC=C2)CCN(C(CC3=C(C)C4=CC5=C(OC6=C5CCCC6)C(C)=C4OC3=O)=O)CC1)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ZINC000002107582 Related Classifications
HY-183987 Related Classifications
Powered by Bioz